Selected culture and drug-susceptibility testing methods for drug-resistant Mycobacterium tuberculosis screening in resource-constrained settings

Expert Review of Molecular Diagnostics

Volumn 13, Issue 3, 2013, Pages 247-249

  Ausina Ruiz, Vicente ^a,b,c,d   Fernández Rivas, Gema ^a,c   Vilaplana Messeguer, Cristina ^b,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b IrsiCaixa Aids Research Institute   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

determination of drug sensitivity; drug resistant tuberculosis; line probe assays; Manual Mycobacteria Growth Indicator Tube; Nitrate Reductase Assay in liquid medium; Xpert Mycobacterium tuberculosis rifampicin

Indexed keywords

RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; DRUG RESISTANT TUBERCULOSIS; DRUG SCREENING; LIQUID CULTURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

EID: 84876122461     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.10     Document Type: Article

References (20)

1. Adikaram CP, Perera J, Wijesundera SS. The manual Mycobacteria Growth Indicator Tube and the Nitrate Reductase Assay for the rapid detection of rifampicin resistance of M. tuberculosis in low resource settings. BMC Infect. Dis. 12, 326 (2012
2. Nathanson E, Nunn P, Uplekar M et al. MDR tuberculosis - critical steps for prevention and control. N. Engl. J. Med. 363(11), 1050-1058 (2010
3. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N. Engl. J. Med. 356(7), 656-659 (2007
4. WHO. The Global Plan to Stop TB, 2011-2015. WHO, Geneva, Switzerland (2010
5. WHO. Global Tuberculosis Report 2012. WHO, Geneva, Switzerland (2012
6. Aziz MA, Wright A, Laszlo A et al.; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368(9553), 2142-2154 (2006
7. Wallis RS, Pai M, Menzies D et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375(9729), 1920-1937 (2010
8. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med. 30(4), 701-716, viii (2009
9. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr. Opin. Pulm. Med. 16(3), 271-284 (2010
10. WHO: Global Tuberculosis Control, WHO Report 2010. WHO, Geneva, Switzerland (2010
11. Stop TB Partnership's New Diagnostic Working Group and WHO. Pathways to Better Diagnostics for Tuberculosis: A Blueprint for the Development of TB Diagnostics. WHO, Geneva, Switzerland (2009
12. Adjers-Koskela K, Katila ML. Susceptibility testing with the manual Mycobacteria Growth Indicator Tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J. Clin. Microbiol. 41(3), 1235-1239 (2003
13. Affolabi D, Odoun M, Sanoussi N et al. Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the Nitrate Reductase Assay using liquid medium and direct application to sputum samples. J. Clin. Microbiol. 46(10), 3243-3245 (2008
14. Visalakshi P, Meharwal SK, Myneedu VP, Behera D. Evaluation of direct method of drug susceptibility testing of Mycobacterium tuberculosis to rifampicin and isoniazid by Nitrate Reductase Assay in a national reference laboratory. Diagn. Microbiol. Infect. Dis. 66(2), 148-152 (2010
15. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The Nitrate Reductase Assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 62(1), 56-64 (2008
16. Chitra C, Prasad CE. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for primary isolation of mycobacteria. Ind. J. Tub. 48(3), 155-156 (2001
17. WHO: Policy Statement. Molecular Line Probe Assays for Rapid Screening of Patients At Risk of Multidrug-Resistant Tuberculosis (MDR-TB). WHO, Geneva, Switzerland (2008
18. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363(11), 1005-1015 (2010
19. Lienhardt C, Raviglione M, Spigelman M et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205(Suppl. 2), S241-S249 (2012
20. Phillips PP, Gillespie SH, Boeree M et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. 205(Suppl. 2), S250-S257 (2012